20 research outputs found

    Real-Time PCR in HIV/Trypanosoma cruzi Coinfection with and without Chagas Disease Reactivation: Association with HIV Viral Load and CD4+ Level

    Get PDF
    Chagas disease is endemic in Latin America and is caused by the flagellate protozoan T. cruzi. The acute phase is asymptomatic in the majority of the cases and rarely causes inflammation of the heart or the central nervous system. Most infected patients progress to a chronic phase, characterized by cardiac or digestive involvement when not asymptomatic. However, when patients are also exposed to an immunosuppressant (such as chemotherapy), neoplasia, or other infections such as HIV, T. cruzi infection may develop into a severe disease (Chagas disease reactivation) involving the heart and central nervous system. The current microscopic methods for diagnosing Chagas disease reactivation are not sensitive enough to prevent the high rate of death observed in these cases. Therefore, we propose a quantitative method to monitor blood levels of the parasite, which will allow therapy to be administered as early as possible, even if the patient has not yet presented symptoms

    Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

    Get PDF
    Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

    Molecular characterization of Trypanosoma cruzi in patients with Chagas\' disease with and without immunesuppression (HIV infection and organ transplantation)

    No full text
    A doença de Chagas é caracterizada por um amplo espectro de manifestações clínicas, que vão desde a ausência de sintomas à doença grave com comprometimento cardíaco e/ou digestivo. A influência do parasito, Trypanosoma cruzi (T. cruzi), agente etiológico da doença, nessas apresentações clínicas têm sido largamente estudada, não se tendo demonstrado o papel da diversidade genética de populações de T. cruzi na determinação das diferentes formas clínicas em humanos. Este trabalho teve como objetivos: a) geral: analisar as características moleculares de T. cruzi em pacientes com doença de Chagas com e sem imunodepressão (infecção por HIV e transplante de órgãos com e sem reativação); b) específicos: 1. Analisar comparativamente isolados do parasito quanto à distribuição em DTU; 2. Relacionar os resultados obtidos pela análise molecular do gene ND7 com a forma clínica e origem; 3. Avaliar por LSSP-PCR a variabilidade da sequência do kDNA de T. cruzi diretamente de amostras biológicas assim como em isolados de T. cruzi obtidos pelos exames de hemocultura/xenodiagnóstico; 4. Comparar os padrões polimórficos obtidos por LSSP-PCR em amostras repetidas de um mesmo paciente no mesmo sítio ou distintos sítios biológicos. Foram incluídos, após aprovação do protocolo na CAPPesq e mediante assinatura de TCLE, 106 pacientes com doença de Chagas crônica ou com imunossupressão, provenientes dos ambulatórios e enfermarias do HCFMUSP, além de 75 indivíduos controle, com provas sorológicas e moleculares negativas. Foram analisadas 187 amostras isoladas de hemocultura/xenodiagnóstico e 236 diretamente de amostras sanguíneas de pacientes. Os seguintes grupos foram constituídos: Agudo-AG, Crônico-CR, Crônico Imunodeprimido-CRI (doenças autoimunes/neoplasias), Coinfecção-CO (infecção por HIV/T.cruzi), Coinfecção-CO/RE (infecção por HIV/T.cruzi e reativação da doença de Chagas), Transplantado-TX, Transplantado-TX/RE (Transplantado com reativação da doença de Chagas). Foram identificados DTU TcI, TcV, TcVI e em maior número TcII, por ensaios de tipagem molecular do parasito, com distribuição estatisticamente significantemente de acordo com a naturalidade dos pacientes (P=0,013). Quanto ao gene ND7, observou-se que a banda de ~900 bp ocorreu em 83,0% das amostras das regiões norte, nordeste, centro-oeste e Bolívia e a de ~400pb em 54% das amostras nas regiões sul e sudeste brasileiras sendo esta diferença estatisticamente significante (P < 0,001). A comparação dos perfis observados por LSSP-PCR a partir de amostras extraídas diretamente do sangue e de isolados obtidos de hemocultura/xenodiagnóstico mostrou maior variabilidade em amostras sanguíneas, confirmada pelo dendrograma. Adicionalmente, o estudo de amostras repetidas do mesmo paciente permitiu confirmar a maior variabilidade nas amostras diretamente extraídas do sangue, com mudança dos padrões durante e após o tratamento com reaparecimento de perfis antigos não presentes no período prétratamento imediato, além de presença de perfis diferentes em distintos sítios biológicos do mesmo paciente. O encontro de DTU diferentes de TcII nos grupos CR/CRI e AG enfatiza a necessidade de atentar para a diferença em limiares de reatividade segundo DTU na análise da parasitemia por PCRq (quantitativa), conforme registrado na literatura. Os dados observados por LSSP-PCR acrescentam informações adicionais não revelados por tipagem molecular, representando novos desafios para o entendimento da relação hospedeiro-parasito em pacientes com doença de Chagas sem e com imunossupressão, ao lado de fatores como nível de parasitemia e pressão seletiva de medicamentos antiparasitários e imunossupressoresChagas\' disease is characterized by a broad spectrum of clinical manifestations, ranging from asymptomatic cases to severe cardiovascular and/or gastrointestinal involvement. The clinical presentations are thought to be determined primarily by genetic diversity of populations of Trypanosoma cruzi (T. cruzi), but no correlation was clearly demonstrated yet. This study aimed to: a) general: to analyze the molecular characteristics of T. cruzi in patients with Chagas\' disease with and without immunosuppression (HIV infection and organ transplantation with or without reactivation); b) specifics: 1.To analyze comparatively isolates from the parasite as for the distribution in DTU; 2. To describe the results obtained by molecular analysis of gene ND7 in relationship with the clinical form and origin; 3. To assess by LSSP-PCR the variability of the sequence of the T. cruzi kDNA directly from biological samples, as well as in T. cruzi isolates obtained by examination of blood culture/xenodiagnosis; 4. To compare the polymorphic patterns obtained by LSSP-PCR in repeated samples of the same patient on the same site or different biological sites. After approval of the protocol in CAPPesq and by signing an informed consent, 106 patients with chronic Chagas disease or immunosuppression, from the HCFMUSP\'s clinics and wards, and 75 control subjects with negative serological and molecular tests were included. They were analyzed 187 isolated samples from blood culture/xenodiagnosis and 236 directly from blood samples of patients. The following groups were formed: Acute-AC, Chronic-CR, Chronic immunocompromised-CRI (autoimmune diseases/ neoplasms), Coinfection-CO (HIV/T. cruzi infection), Coinfection-CO/RE (HIV/T. cruzi and reactivation of Chagas disease), Transplantation-TX, Transplantation-TX/RE (Transplantation/ with reactivation of Chagas\' disease). DTU TcI, TcV, TcVI and higher TcII number were identified for molecular typing assays of the parasite and the distribution of DTU was statistically significant according to patient´s naturality (P=0.013). As for ND7 gene, was observed that the band of ~ 900 bp was prevalent in 83% of the samples in the North, Northeast, Midwest regions and Bolivia and the band of ~400bp occurred in 54% of the samples of Brazilian\' South and Southeast regions, this distribution was statistically significant (P < 0.001). The comparison between the profiles observed by LSSP-PCR from samples taken directly from blood and isolates obtained from blood culture/xenodiagnosis showed greater variability in blood samples, confirmed by dendrogram. Additionally, the study of repeated samples from the same patient allowed to confirm the greater variability in blood samples taken directly, with changing patterns during and after the treatment with reappearance of old profiles not present in the immediate pre-treatment period, and the presence of different profiles at different biological sites in the same patient. The presence of other DTUs than TcII in chronic and chronic immunosuppressed patients and AC groups emphasizes the need to pay attention to the different reactivity thresholds for the various DTU in the analysis of parasitaemia by PCRq (quantitative), according to the data registered in the literature. The results observed by LSSP-PCR add further information not revealed by molecular typing, representing new challenges for the understanding of the host-parasite relationship in patients with Chagas\' disease with and without immunosuppression, alongside factors such as level of parasitaemia and selective pressure of antiparasitic drugs and immunosuppressiv

    Vírus rábico em morcego Nyctinomops laticaudatus na Cidade do Rio de Janeiro, RJ: isolamento, titulação e epidemiologia

    No full text
    Apresenta-se o primeiro relato de raiva em morcego da espécie Nyctinomops laticaudatus, na Cidade do Rio de Janeiro, RJ. Foram realizados isolamento e titulação viral em diferentes tecidos, encontrando-se altos títulos no cérebro e glândulas salivares. A ocorrência de raiva em uma espécie pouco freqüente neste estado sugere que a doença pode ser mais prevalente do que aparenta

    CHAGASIC MENINGOENCEPHALITIS IN AN HIV INFECTED PATIENT WITH MODERATE IMMUNOSUPPRESSION: PROLONGED SURVIVAL AND CHALLENGES IN THE HAART ERA

    Get PDF
    The reactivation of Chagas disease in HIV infected patients presents high mortality and morbidity. We present the case of a female patient with confirmed Chagasic meningoencephalitis as AIDS-defining illness. Interestingly, her TCD4+ lymphocyte cell count was 318 cells/mm3. After two months of induction therapy, one year of maintenance with benznidazol, and early introduction of highly active antiretroviral therapy (HAART), the patient had good clinical, parasitological and radiological evolution. We used a qualitative polymerase chain reaction for the monitoring of T. cruzi parasitemia during and after the treatment. We emphasize the potential value of molecular techniques along with clinical and radiological parameters in the follow-up of patients with Chagas disease and HIV infection. Early introduction of HAART, prolonged induction and maintenance of antiparasitic therapy, and its discontinuation are feasible, in the current management of reactivation of Chagas disease.A reativação da doença de Chagas em pacientes com a infecção pelo HIV apresenta uma alta morbidade e mortalidade. Neste relato, apresentamos caso confirmado de meningoencefalite chagásica, como doença definidora de aids, em paciente com 318 linfócitos T-CD4+/mm3. Após 2 meses de tratamento seguido de um ano de profilaxia secundária com benzonidazol e início precoce de terapia antirretroviral (HAART), a paciente apresentou boa evolução clínica, parasitológica e radiológica. Utilizamos a reação em cadeia da polimerase qualitativa do T. cruzi, para monitorização da parasitemia por T. cruzi durante e após o tratamento. Ressaltamos o valor potencial das técnicas moleculares associadas aos parâmetros clínicos e radiológicos nos pacientes com doença de Chagas e infecção pelo HIV. A introdução precoce da terapia antirretroviral, a terapia antiparasitária prolongada, manutenção e descontinuação da mesma, são desafios atuais, embora possíveis, no manejo da reativação da doença de Chagas na era das terapias antirretrovirais de alta eficácia

    Comportamento de pastejo de bezerras recebendo ou não suplemento em pastagem de azevém

    No full text
    We evaluated the grazing behavior of heifers, at two phenological stages (vegetative and reproductive) of ryegrass (Lolium multiflorum Lam.), in four times of the day (early morning, morning, evening, and night), with heifers either exclusively grazing or with oat, or corn grain, supplementation. The experimental design was completely randomized, in sub-subdivided plot arrangement, in which the main plots were the feeding systems, the sub-plots were the phenological stages and the sub-sub-plots were the times of day. We assessed ingestion behavior along 24 hours through visual observation, on four evaluation dates, two during the vegetative stage and two during the reproductive stage, studying time spent on grazing, rumination, or other activities, as well as number and duration of, and interval between meals. Supplemented heifers remained less time at a feeding station, performed fewer bites daily and, during the reproductive stage of the ryegrass, spent more time in other activities. Grazing time of supplemented heifers was shorter in the morning and at night, and the duration of their meals was shorter at night. A change occurred in the pattern of time use when heifers received supplement, and when the structural and qualitative characteristics of the pasture changed during the vegetative and reproductive phenological stages of ryegrass.O experimento foi desenvolvido com o objetivo de avaliar o comportamento de pastejo de bezerras, durante dois estádios fenológicos do azevém (Lolium multiflorum Lam.), em quatro turnos diários (madrugada, manhã, tarde, noite). As bezerras estavam exclusivamente em pastejo ou em pastejo e recebendo suplemento (grão de aveia ou de milho). O delineamento experimental foi inteiramente casualizado, seguindo a estrutura de parcelas sub-subdivididas sendo os sistemas alimentares as parcelas principais, os estádios fenológicos as sub-parcelas e os turnos diários as sub-subparcelas. O registro do comportamento ingestivo foi realizado durante 24 horas, por observação visual, em quatro datas de avaliação: duas no estádio vegetativo e duas no estádio reprodutivo do azevém. Avaliaram-se os tempos de pastejo, de ruminação e de outras atividades, além do número, tempo de duração e o intervalo entre refeições das bezerras suplementadas ou não em pastagem de azevém. As bezerras que receberam suplemento permaneceram menor tempo na estação alimentar e realizaram menor número de bocados diários. No estádio reprodutivo do azevém, as bezerras suplementadas permaneceram por mais tempo em outras atividades. O tempo de pastejo das bezerras que receberam suplemento foi menor nos turnos da manhã e noite. A duração das refeições foi menor no período noturno para as bezerras suplementadas. O padrão do uso do tempo das bezerras foi alterado pelo recebimento de suplemento e pela mudança das características estruturais e qualitativas do azevém durante os estádios de desenvolvimento vegetativo e reprodutivo

    C-PCR and qRT-PCR in the blood of patients' groups (CR, CO and RE).

    No full text
    <p><b>A)</b> Number of <i>T. cruzi</i>/mL (log<sub>10</sub>) in blood by C-PCR. CR (<i>n</i> = 17); CO (<i>n</i> = 16) and RE (<i>n</i> = 5). The line represents the median. Comparative analysis among the groups showed a statistically significant difference (<i>P</i><0.001) by Kruskal–Wallis test. Comparing the groups, a statistically significant difference was observed between CR×CO, <i>P</i><0.001; CR×RE, <i>P</i><0.001; and CO×RE, <i>P</i>>0.05) (Dunn s Multiple Comparison test). <b>B)</b> Number of <i>T. cruzi</i>/mL (log<sub>10</sub>) in blood by qRT-PCR. CR (<i>n</i> = 57); CO (<i>n</i> = 29) and RE (<i>n</i> = 5). Comparison of the qRT-PCR results observed in the three groups of patients with Chagas disease. The results revealed a statistically significant difference (<i>P</i><0.001) by Kruskal–Wallis test, and comparison between the groups showed statistically significant differences between CR×CO (<i>P</i><0.001), CR×RE (<i>P</i><0.001), and CO×RE, (<i>P</i><0.05) (Dunn's Multiple Comparison test).</p

    Results of xenodiagnosis<sup>a</sup>, C-PCR<sup>b</sup> and qRT-PCR<sup>c</sup> in the three groups of patients<sup>d</sup> (CO, CR, RE).

    No full text
    a<p>XD - Xenodiagnosis (% of nymphs positive per assay) was performed in 90 patients,</p>b<p>C-PCR (number of parasites) in 38 patients and</p>c<p>qRT-PCR in 91 patients (Ct for 53 positive samples and number of parasites for 91 patients = 91 samples),</p>d<p>groups of patients: chronic Chagas disease with (CO, 29 patients) and without HIV infection (CR, 57 patients) and reactivation of Chagas disease in HIV infected patients (RE, 5 patients).</p

    Sensitivities of the qualitative PCR<sup>a</sup>, xenodiagnosis<sup>b</sup> and blood culture<sup>c</sup> in Chagas disease with/without HIV infection.

    No full text
    a<p>qualitative S35/36 PCR,</p>b<p>xenodiagnosis (XD),</p>c<p>blood culture (BC),</p>d<p>groups of patients: chronic Chagas disease with (CO) and without HIV infection (CR) and reactivation of Chagas disease in HIV infected patients (RE). Xenodiagnosis was not performed on three samples from chronic chagasic patients. Blood culture was not performed on one sample from co-infected patient.</p
    corecore